Pulmatrix (NASDAQ:PULM – Get Free Report) issued its earnings results on Monday. The biotechnology company reported ($0.34) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.00) by $1.66, FiscalAI reports.
Pulmatrix Stock Up 3.1%
Shares of PULM stock opened at $1.33 on Tuesday. Pulmatrix has a fifty-two week low of $1.06 and a fifty-two week high of $4.98. The stock has a market cap of $4.86 million, a P/E ratio of -1.21 and a beta of 1.95. The business has a fifty day simple moving average of $1.46 and a 200-day simple moving average of $1.65.
Wall Street Analyst Weigh In
Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Pulmatrix in a research note on Thursday. One analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, Pulmatrix presently has an average rating of “Sell”.
Read Our Latest Analysis on Pulmatrix
About Pulmatrix
Pulmatrix, Inc. is a clinical-stage biopharmaceutical company developing inhaled therapies. Its proprietary iSPERSE technology is designed to deliver dry-powder medicines to the lungs, and the company’s work has included treatments for respiratory diseases as well as medicines delivered through the lungs for other conditions. Among its drug candidates, PUR1900 is an inhaled formulation of itraconazole being developed for allergic bronchopulmonary aspergillosis, a lung condition associated with fungal sensitivity.
Read More
- Five stocks we like better than Pulmatrix
- Microsoft’s Outage Barely Moved Its Stock, But a Bigger Risk May Be Building
- MongoDB’s Biggest Advantage May Be GitLab’s Biggest Weakness
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
Receive News & Ratings for Pulmatrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix and related companies with MarketBeat.com's FREE daily email newsletter.
